EGFR and neoplasm: Considering that the patient had EGFR 21 exon L858R mutation, she was treated with oral aumolertinib 110 mg/day in January 2021, and after nearly 2 months of treatment, chest CT indicated significant regression of the left hilar lymph nodes, and the mass volume was reduced to 1.2 × 1.0 × 1.5 cm, achieving PR; clinical stage was reduced to stage IB (T2N0M0); and the tumor was clearly demarcated from the left pulmonary artery trunk, which could be considered for surgical radical treatment.